Citation

  • Authors: Shao A. et al.
  • Year: 2020
  • Journal: Oncogene 39 2807-2818
  • Applications: in vitro / DNA / jetPRIME
  • Cell types:
    1. Name: HCT 116
      Description: Human colon carcinoma cells
      Known as: HCT116
    2. Name: HEK-293T
      Description: Human embryonic kidney Fibroblast
      Known as: HEK293T, 293T
    3. Name: HeLa
      Description: Human cervix epitheloid carcinoma cells
    4. Name: Hep G2
      Description: Human hepatocarcinoma cells
    5. Name: IMR-90
      Description: Human lung cells
    6. Name: NCI-H1299

Abstract

Hypoxic stress is intimately connected with tumor progression, with hypoxia-inducible factor-1? (HIF-1?) being a critical regulator in this process. HIF-1? is stabilized in response to hypoxia, which is required for the induction of gene transcriptions important for hypoxic adaptation. Bclaf1 is a multifunctional protein involved in tumorigenesis, however, its role in this process is not well characterized. Here we report Bclaf1 is a direct transcriptional target of HIF-1 and upregulated in multiple cell lines during hypoxia. Importantly, we found Bclaf1 is involved in the stabilization of HIF-1? during long-term hypoxic treatments. Compared with the control cells, the protein level and stability of HIF-1? in Bclaf1 knockdown or knockout cells is greatly compromised after long-term hypoxic treatments, concomitant with the impaired inductions of HIF-1 target gene transcription. Bclaf1 knockout HeLa cells exhibit a reduced tumor growth in mice xenografts, in which the expressions of HIF-1? and its target genes are also decreased. Bclaf1 binds to HIF-1? in the nucleus, and this interaction is required for Bclaf1 to stabilize HIF-1? in hypoxic condition. These results uncover a positive feedback loop, HIF-1-Bclaf1, that sustains HIF-1 activity during long-term hypoxic conditions by binding to and protecting HIF-1? from degradation, and suggest that Bclaf1 may promote tumor progression by enhancing HIF-1? stability.

Pubmed